EP1121117B1 - Conditionnement d'une preparation d'oxaliplatine - Google Patents

Conditionnement d'une preparation d'oxaliplatine Download PDF

Info

Publication number: EP1121117B1
Authority: EP; European Patent Office
Prior art keywords: oxaliplatinum; flexible; bag; pharmaceutical preparation; medical use
Prior art date: 1998-10-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

EP99946400A

Other languages

German (de)

English (en)

French (fr)

Other versions

EP1121117A2 (fr

Inventor

Rolland-Yves Mauvernay

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Debiopharm SA

Original Assignee

Debiopharm SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-14

Filing date

1999-10-13

Publication date

2002-06-05

1999-10-13 Application filed by Debiopharm SA filed Critical Debiopharm SA

2001-08-08 Publication of EP1121117A2 publication Critical patent/EP1121117A2/fr

2002-06-05 Application granted granted Critical

2002-06-05 Publication of EP1121117B1 publication Critical patent/EP1121117B1/fr

2019-10-13 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Definitions

the present invention relates to a pocket flexible waterproof for medical use containing a pharmaceutical preparation oxaliplatin.
This pharmaceutical preparation has been stored in vials in neutral glass for pharmaceutical use under a gas atmosphere inert.
bottles if they are suitable for the long-term storage of the pharmaceutical preparation, are not to contain this preparation during administration by infusion.
PVC polyvinyl chloride
the purpose of the present invention is to provide Oxaliplatin pharmaceutical liquid preparations which can be not only kept over a long period of time without no loss of quality can be noted, but also which can be used in particular for infusion operations without that no transfer operation for liquid preparations pharmaceutical is only to be performed by nursing staff
the present invention relates to a flexible pocket waterproof for medical use containing a pharmaceutical preparation oxaliplatin in liquid form as defined in claim 1.
the different variants are such that defined in claims 2 to 9.
the pharmaceutical preparation of oxaliplatin according to the present invention is stored, then used directly, in a flexible pocket and flexible made from plastic materials chosen from polyethylenes (PE), polypropylenes (PP), polyethyl acetates and vinyl, polyamides (PA), polyisobutyls (PIB). Latex can also be used.
PE polyethylenes
PP polypropylenes
PA polyethyl acetates and vinyl
PA polyamides
PIB polyisobutyls
the envelope of the pocket has preferably a multilayer structure. More preferably, the layer internal which is in direct contact with the pharmaceutical preparation consists of PP, the outer layer or any layers intermediates which may consist of any of the plastics previously mentioned. The outer layer or any layers intermediates can even be made of PVC, oxaliplatin does not not in direct contact with this material.
the flexible pouch of the invention is preferably made up of a material made of 70% PP and 30% PA 11 and commonly called V90.
This oxygen tightness property is very important considering the sensitivity of oxaliplatin to oxidizing products, the degradation products generated during such oxidation being general pharmacologically inactive and may even be toxic to the body. This quality is entirely appropriate when the use of flexible pouches which have the advantage, compared to the bottles in glass, not to require the presence of an inert gas atmosphere.
the material V90 also offers the advantage from the point of view ecological to be recycled and to be used in another form, which is not not the case with PVC.
the materials mentioned above, and in particular PP (V90), also have the advantage of better supporting high temperatures. This is particularly interesting during sterilization flexible bags containing an oxaliplatin solution by autoclave. This sterilization is much easier because by increasing the temperature we can thus reduce the exposure time.
the liquid solution of oxaliplatin contained in these bags has preferably a concentration between 1 and 8 mg / ml.
the concentration of oxaliplatin is between 1 and 5 mg / ml with a pH between 4 and 7, ideally between 4.5 and 6.
the oxaliplatin content in the preparation according to a particular form of the invention contains at least 95% of the initial content and has a clear colorless appearance without precipitate after storage for a pharmaceutically acceptable period.
liquid solution of oxaliplatin packaged in flexible pouch is stable for a period going on a period well beyond three months, and even beyond six months.
this liquid solution of oxaliplatin packaged in a bag appears to remain stable for at least a year.
Fig. 6 shows the change in pH over 12 weeks. This pH is between 4.7 and 5.9 and varies very little over time, which proves well that the oxaliplatin solution remains stable in this type of bag. This system has a stability similar to that observed for a solution of oxaliplatin subject to the same conditions and packaged in a vial of glass as shown in Fig. 7.
Oxaliplatin pharmaceutical preparations can be stored, without any chemical degradation of oxaliplatin being observed, over a long period in flexible pockets, from the moment it is not in direct contact with a PVC-based material.
Oxaliplatin pharmaceutical preparations due to the flexibility of the materials constituting the pockets, are found to be ready for use in transfusion without any transfer operation being necessary.

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

EP99946400A 1998-10-14 1999-10-13 Conditionnement d'une preparation d'oxaliplatine Expired - Lifetime EP1121117B1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CH206798		1998-10-14
CH206798		1998-10-14
PCT/IB1999/001670 WO2000021527A2 (fr)	1998-10-14	1999-10-13	Conditionnement d'une preparation d'oxaliplatine

Publications (2)

Publication Number	Publication Date
EP1121117A2 EP1121117A2 (fr)	2001-08-08
EP1121117B1 true EP1121117B1 (fr)	2002-06-05

Family

ID=4225128

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP99946400A Expired - Lifetime EP1121117B1 (fr)	1998-10-14	1999-10-13	Conditionnement d'une preparation d'oxaliplatine

Country Status (14)

Country	Link
US (1)	US6866857B1 (es)
EP (1)	EP1121117B1 (es)
JP (1)	JP4884587B2 (es)
AT (1)	ATE218337T1 (es)
AU (1)	AU762138B2 (es)
BR (1)	BRPI9914508B8 (es)
CA (1)	CA2346564C (es)
DE (1)	DE69901725T2 (es)
DK (1)	DK1121117T3 (es)
ES (1)	ES2178474T3 (es)
HK (1)	HK1039280B (es)
MX (1)	MXPA01003799A (es)
PT (1)	PT1121117E (es)
WO (1)	WO2000021527A2 (es)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006072440A1 (de) *	2004-12-29	2006-07-13	Hexal Ag	Kunststoff-flasche für oxaliplatinlösung
US7829113B2 (en)	2005-03-10	2010-11-09	Mebiopharm Co., Ltd.	Liposome compositions
US7888523B2 (en)	2004-09-01	2011-02-15	Platco Technologies (Proprietary) Limited	Preparation of platinum(II) complexes
US7888390B2 (en)	2003-11-25	2011-02-15	Platco Technologies (Proprietary) Limited	Preparation of platinum(II) complexes
US7956208B2 (en)	2006-01-30	2011-06-07	Platco Technologies (Proprietary) Limited	Preparation of platinum (II) complexes

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002047725A2 (fr) *	2000-12-12	2002-06-20	Debiopharm S.A.	Preparation pharmaceutique d'oxaliplatine pour administration par voie parenterale et procede d'obtention de ladite preparation
ES2287238T3 (es)	2001-03-02	2007-12-16	Debiopharm S.A.	Utilizacion de un vial que contiene una solucion de oxaliplatino.
EP1404689A1 (en) *	2001-07-02	2004-04-07	Debiopharm S.A.	Oxaliplatin active substance with a very low content of oxalic acid
US6476068B1 (en)	2001-12-06	2002-11-05	Pharmacia Italia, S.P.A.	Platinum derivative pharmaceutical formulations
DE102004063347A1 (de) *	2004-12-23	2006-07-13	Stada Arzneimittel Ag	Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6041077B2 (ja)	1976-09-06	1985-09-13	喜徳喜谷	１，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
JPS60199456A (ja) *	1984-03-26	1985-10-08	住友ベークライト株式会社	血液バツグ
US5492534A (en) *	1990-04-02	1996-02-20	Pharmetrix Corporation	Controlled release portable pump
JP3212679B2 (ja) *	1992-03-31	2001-09-25	出光興産株式会社	医療用輸液バッグ
CN1138541C (zh) *	1994-08-08	2004-02-18	德彪药品股份有限公司	一种药学上稳定的奥沙利铂制剂
JPH08155007A (ja) *	1994-12-02	1996-06-18	Mitsui Petrochem Ind Ltd	薬剤充填容器製剤及びこれに用いる容器
DE19542716A1 (de) *	1995-11-16	1997-05-22	Braun Melsungen Ag	Polymer-Composit-Schlauchfolie
SE9601348D0 (sv) *	1996-04-10	1996-04-10	Pharmacia Ab	Improved containers for parenteral fluids
ATE338553T1 (de) *	1997-03-07	2006-09-15	Sanofi Aventis Us Llc	Antitumorkombination aus 3-amino-1,2,4- benzotriazine 1,4-dioxid/paclitaxel/platin
GB9804013D0 (en)	1998-02-25	1998-04-22	Sanofi Sa	Formulations

1999
- 1999-10-13 CA CA2346564A patent/CA2346564C/fr not_active Expired - Lifetime
- 1999-10-13 MX MXPA01003799A patent/MXPA01003799A/es active IP Right Grant
- 1999-10-13 BR BRPI9914508A patent/BRPI9914508B8/pt not_active IP Right Cessation
- 1999-10-13 AU AU58807/99A patent/AU762138B2/en not_active Expired
- 1999-10-13 DE DE69901725T patent/DE69901725T2/de not_active Expired - Lifetime
- 1999-10-13 US US09/807,586 patent/US6866857B1/en not_active Expired - Lifetime
- 1999-10-13 WO PCT/IB1999/001670 patent/WO2000021527A2/fr active IP Right Grant
- 1999-10-13 JP JP2000575503A patent/JP4884587B2/ja not_active Expired - Lifetime
- 1999-10-13 EP EP99946400A patent/EP1121117B1/fr not_active Expired - Lifetime
- 1999-10-13 ES ES99946400T patent/ES2178474T3/es not_active Expired - Lifetime
- 1999-10-13 PT PT99946400T patent/PT1121117E/pt unknown
- 1999-10-13 DK DK99946400T patent/DK1121117T3/da active
- 1999-10-13 AT AT99946400T patent/ATE218337T1/de active
2002
- 2002-02-04 HK HK02100838.4A patent/HK1039280B/zh unknown

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7888390B2 (en)	2003-11-25	2011-02-15	Platco Technologies (Proprietary) Limited	Preparation of platinum(II) complexes
US7888523B2 (en)	2004-09-01	2011-02-15	Platco Technologies (Proprietary) Limited	Preparation of platinum(II) complexes
WO2006072440A1 (de) *	2004-12-29	2006-07-13	Hexal Ag	Kunststoff-flasche für oxaliplatinlösung
US7829113B2 (en)	2005-03-10	2010-11-09	Mebiopharm Co., Ltd.	Liposome compositions
US8758810B2 (en)	2005-03-10	2014-06-24	Mebiopharm Co., Ltd.	Liposome compositions
US7956208B2 (en)	2006-01-30	2011-06-07	Platco Technologies (Proprietary) Limited	Preparation of platinum (II) complexes

Also Published As

Publication number	Publication date
WO2000021527A3 (fr)	2000-08-17
ATE218337T1 (de)	2002-06-15
ES2178474T3 (es)	2002-12-16
EP1121117A2 (fr)	2001-08-08
US6866857B1 (en)	2005-03-15
PT1121117E (pt)	2002-10-31
BRPI9914508B8 (pt)	2021-05-25
MXPA01003799A (es)	2003-06-09
HK1039280B (zh)	2003-02-14
WO2000021527A2 (fr)	2000-04-20
BR9914508A (pt)	2001-10-30
HK1039280A1 (en)	2002-04-19
JP2002527390A (ja)	2002-08-27
CA2346564A1 (fr)	2000-04-20
DE69901725T2 (de)	2003-01-30
BRPI9914508B1 (pt)	2021-04-20
DE69901725D1 (de)	2002-07-11
DK1121117T3 (da)	2002-09-16
AU5880799A (en)	2000-05-01
JP4884587B2 (ja)	2012-02-29
CA2346564C (fr)	2011-05-03
AU762138B2 (en)	2003-06-19

Publication	Publication Date	Title
CA2196922C (fr)	2004-06-01	Preparation pharmaceutiquement stable d'oxaliplatine
EP1909739B1 (en)	2010-12-29	Multiple chamber container
EP1121117B1 (fr)	2002-06-05	Conditionnement d'une preparation d'oxaliplatine
WO1999039679A1 (fr)	1999-08-12	Support de solution de vitamine d et recipients pour l'administration
TWI474840B (zh)	2015-03-01	綜合營養輸液劑
KR20020081293A (ko)	2002-10-26	페메트렉시드를 모노티오글리세롤 ｌ-시스테인 또는티오글리콜산과 함께 포함하는 제약 조성물
JP4162306B2 (ja)	2008-10-08	中心静脈投与用輸液
US20110046100A1 (en)	2011-02-24	Texaphyrin solutions and pharmaceutical formulations
JP2019506407A (ja)	2019-03-07	酸化感受性製剤のための安定なすぐ使用できる注入バッグを製造するプロセス
JP2021175713A (ja)	2021-11-04	スガマデクス又はその薬理学的に許容される塩含有液剤
JP4488907B2 (ja)	2010-06-23	医療用二重包装製剤の製造方法および医療用二重包装製剤
TWI623310B (zh)	2018-05-11	被包裝的乙醯胺苯酚注射溶液製劑
JP2009285318A (ja)	2009-12-10	ガスバリア容器の包装形態
JPWO2007074641A1 (ja)	2009-06-04	白金錯体を含有する水溶液医薬製剤
JP7051999B2 (ja)	2022-04-11	ペメトレキセドの静脈内注入剤形
JP2006020657A (ja)	2006-01-26	微量元素配合輸液製剤
JP2006342058A (ja)	2006-12-21	プラスチック製容器入りシスプラチン製剤
WO2003002139A1 (fr)	2003-01-09	Procede permettant d'ameliorer la stabilite de la preparation de proteines
JP2022148904A (ja)	2022-10-06	液状製剤及び液状製剤入り製剤容器
FR3144527A3 (fr)	2024-07-05	Systeme de preparation d’hydrosol
WO2007040529A1 (en)	2007-04-12	Storage system for texaphyrin pharmaceutical formulations
JPH0687271U (ja)	1994-12-22	液体容器

Legal Events

Date	Code	Title	Description
2001-06-22	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2001-08-08	17P	Request for examination filed	Effective date: 20010426
2001-08-08	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2001-08-08	AX	Request for extension of the european patent	Free format text: AL;LT;LV;MK;RO;SI
2001-09-05	RIC1	Information provided on ipc code assigned before grant	Free format text: 7A 61K 31/282 A, 7A 61K 33/24 B, 7A 61K 9/08 B, 7A 61K 31/555 B, 7A 61P 35/00 B
2001-09-12	RIC1	Information provided on ipc code assigned before grant	Free format text: 7A 61K 31/282 A, 7A 61K 33/24 B, 7A 61K 9/08 B, 7A 61K 31/555 B, 7A 61P 35/00 B
2001-09-25	GRAG	Despatch of communication of intention to grant	Free format text: ORIGINAL CODE: EPIDOS AGRA
2001-11-14	17Q	First examination report despatched	Effective date: 20010927
2001-11-26	GRAG	Despatch of communication of intention to grant	Free format text: ORIGINAL CODE: EPIDOS AGRA
2001-11-26	GRAH	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOS IGRA
2002-02-26	GRAH	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOS IGRA
2002-04-19	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2002-06-05	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2002-06-05	REF	Corresponds to:	Ref document number: 218337 Country of ref document: AT Date of ref document: 20020615 Kind code of ref document: T
2002-06-05	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH
2002-06-14	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2002-07-10	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D Free format text: FRENCH
2002-07-11	REF	Corresponds to:	Ref document number: 69901725 Country of ref document: DE Date of ref document: 20020711
2002-08-28	GBT	Gb: translation of ep patent filed (gb section 77(6)(a)/1977)	Effective date: 20020801
2002-08-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: NV Representative=s name: KELLER & PARTNER PATENTANWAELTE AG
2002-09-16	REG	Reference to a national code	Ref country code: DK Ref legal event code: T3
2002-10-31	REG	Reference to a national code	Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20020730
2002-11-01	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20020402810 Country of ref document: GR
2002-12-16	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2178474 Country of ref document: ES Kind code of ref document: T3
2003-04-15	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2003-04-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2003-05-28	26N	No opposition filed	Effective date: 20030306
2005-11-16	REG	Reference to a national code	Ref country code: GB Ref legal event code: 732E
2006-07-14	REG	Reference to a national code	Ref country code: CH Ref legal event code: PLI Owner name: SANOFI-AVENTIS Free format text: DEBIOPHARM S.A.#17, RUE DES TERREAUX, CASE POSTALE 82#1000 LAUSANNE 9 (CH) -TRANSFER TO- SANOFI-AVENTIS#174, AVENUE DE FRANCE#75635 PARIS CEDEX 13 (FR)
2006-09-29	REG	Reference to a national code	Ref country code: PT Ref legal event code: QB4A Owner name: SANOFI-AVENTIS, FR Effective date: 20060705
2006-11-01	REG	Reference to a national code	Ref country code: ES Ref legal event code: GD2A Effective date: 20061010
2006-11-03	REG	Reference to a national code	Ref country code: FR Ref legal event code: CL
2007-01-02	NLUE	Nl: licence registered with regard to european patents	Effective date: 20061115
2008-12-10	REG	Reference to a national code	Ref country code: GB Ref legal event code: S72Z
2008-12-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20080919 Year of fee payment: 10
2009-06-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 20060629
2015-03-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: EIGERSTRASSE 2 POSTFACH, 3000 BERN 14 (CH)
2015-10-23	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17
2016-10-20	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 18
2017-10-24	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 19
2018-10-22	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 20
2018-11-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: LU Payment date: 20181019 Year of fee payment: 20
2018-12-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: PT Payment date: 20180920 Year of fee payment: 20 Ref country code: NL Payment date: 20181019 Year of fee payment: 20
2019-01-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: DK Payment date: 20181023 Year of fee payment: 20 Ref country code: IE Payment date: 20181023 Year of fee payment: 20 Ref country code: SE Payment date: 20181019 Year of fee payment: 20 Ref country code: FI Payment date: 20181022 Year of fee payment: 20 Ref country code: GR Payment date: 20181011 Year of fee payment: 20 Ref country code: MC Payment date: 20181012 Year of fee payment: 20 Ref country code: DE Payment date: 20181019 Year of fee payment: 20 Ref country code: AT Payment date: 20181022 Year of fee payment: 20
2019-02-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: BE Payment date: 20181019 Year of fee payment: 20 Ref country code: ES Payment date: 20181123 Year of fee payment: 20 Ref country code: FR Payment date: 20181022 Year of fee payment: 20 Ref country code: IT Payment date: 20181022 Year of fee payment: 20 Ref country code: CH Payment date: 20181019 Year of fee payment: 20
2019-04-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CY Payment date: 20181010 Year of fee payment: 20
2019-10-13	REG	Reference to a national code	Ref country code: DE Ref legal event code: R071 Ref document number: 69901725 Country of ref document: DE
2019-10-14	REG	Reference to a national code	Ref country code: DK Ref legal event code: EUP Effective date: 20191013
2019-10-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2019-10-16	REG	Reference to a national code	Ref country code: NL Ref legal event code: MK Effective date: 20191012
2019-11-25	REG	Reference to a national code	Ref country code: BE Ref legal event code: MK Effective date: 20191013
2019-11-27	REG	Reference to a national code	Ref country code: IE Ref legal event code: MK9A
2019-12-03	REG	Reference to a national code	Ref country code: SE Ref legal event code: EUG
2019-12-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK07 Ref document number: 218337 Country of ref document: AT Kind code of ref document: T Effective date: 20191013
2020-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20191013 Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20191024
2020-09-01	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20200901
2020-10-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20191014